I have used Ellansé since 2017, and I like it. I also see patients who come to me with lumps, bumps or firm areas after Ellansé, often worried that nothing can be done because it cannot be dissolved like hyaluronic acid filler.
A lump after Ellansé is not one condition. Some are simply concentrated product. Some are inflammatory. A few are true granulomas. Management depends on which it is, so my first step is always to find out.

What Ellansé is

Ellansé is a collagen stimulator made of polycaprolactone (PCL) microspheres in a carboxymethylcellulose gel.1 The gel gives some immediate volume and is gradually absorbed; the microspheres stay longer and stimulate collagen around them. The versions differ mainly in how long the PCL lasts: Ellansé S is described as lasting about one year and Ellansé M about two.1
Because Ellansé is not hyaluronic acid, it is not broken down by hyaluronidase. That is why a lump after Ellansé is managed differently from a lump after hyaluronic acid filler, which I explain in my article on dissolving filler.

Not every Ellansé lump is the same thing

Patients often call any lump a granuloma. In practice, a lump after Ellansé can be several different things, and they are managed differently.
What it may beWhat it can relate to
Early, non-inflammatory depositProduct concentration, a bolus, placement too superficial, or a large volume in one area. The Ellansé recommendations link nodules of this kind mainly to technique.1
Firm area or fibrosisA thickened area rather than a distinct lump, sometimes reflecting the collagen response itself.
Delayed inflammatory noduleAn immune-mediated reaction appearing weeks or months later, not necessarily linked to how the product was injected.
Foreign-body granulomaGranulomas after PCL filler have been reported, including late-onset cases.2,3 This is a specific diagnosis, not another word for a lump.
InfectionPain, heat, redness or discharge. This has to be considered before anything anti-inflammatory is injected.
Something that does not fitAn unusual appearance, behaviour or timing, which may need further investigation.
So a lump does not automatically mean the product was injected badly. Some lumps relate to volume and placement; others are the body’s own reaction and can occur even when the injection was done well.

Before I inject anything, I want to know what I am treating

My assessment starts with your history and an examination, then high-frequency ultrasound with Doppler. The scan shows where the product is and how deep, whether there is one deposit or several, whether the area looks inflamed or vascular, and what it sits next to. Ultrasound has been used in published Ellansé cases both to characterise nodules and to guide and confirm their treatment.4,5
Ultrasound shows what a lump is made of and where it sits, which is why I scan before I treat.
More about how I scan in facial ultrasound mapping.

When ultrasound is not enough

Ultrasound is usually my first-line imaging. But if a lesion looks atypical or unusually vascular, extends beyond what I can confidently characterise on ultrasound, or the history and the images do not match, I may recommend MRI, aspiration or biopsy, or a specialist opinion rather than simply injecting into it. I compare the two imaging methods in MRI vs ultrasound for filler complications.

How I manage Ellansé lumps

Depending on what I find clinically and on ultrasound, management can be completely different from one patient to another. Some lesions simply need monitoring. In selected Ellansé nodules, ultrasound-guided treatment may be considered.
Collagenase is one option that has now been described in the medical literature for selected Ellansé nodules,6 although I do not regard it as a universal “dissolver” for Ellansé. In inflammatory lesions, other intralesional approaches, including 5-fluorouracil (5-FU), may sometimes be considered. The evidence for each of these is still limited to small case series and case reports,4,6,7 and the treatment depends on what the lesion actually represents.
Many Ellansé lumps can be managed or substantially improved once we understand what the lesion actually is. Rare refractory cases of collagen-stimulator nodules have needed systemic treatment or surgery,7 which is another reason not to rush into injecting before the diagnosis is clear.
I do not publish doses, concentrations or treatment recipes. They depend on what is found, and a protocol copied from a website is not a substitute for an examination.

Why I do not automatically inject steroid into every Ellansé lump

Corticosteroids have long been used for inflammatory PCL nodules and granulomatous reactions, sometimes together with 5-FU, and they can be appropriate in selected cases. A published case of delayed PCL nodules was treated successfully with ultrasound-guided steroid.5
However, I am cautious with intralesional steroid in the face, because local steroid can itself cause thinning of the skin, loss of fat beneath it and pigment change.8 I prefer first to understand the lesion, its depth and its ultrasound characteristics before deciding whether steroid is justified.

Ellansé in the nose

Ellansé has been described for nasal treatment in the literature.1 Personally, I do not use PCL filler in the nose. If you have had it there and now have a lump or irregularity, it can still be assessed.

How I try to reduce the risk

  • Volume. My personal practice is a maximum of 2 ml of Ellansé in one session. This is my own limit, not an Ellansé guideline.
  • Small amounts. I place small amounts at a limited number of structural points, usually following an eight-point approach, rather than larger boluses. The Ellansé recommendations also advise small, gradual amounts and avoiding overcorrection.1
  • Even delivery. With a cannula, product can build up and be released in one larger amount; I take care to deliver it evenly.
  • Caution in the jawline and chin, where larger amounts are often used and where I see deposits most often.

Lump after Ellansé?

Send me when you had Ellansé, which version if you know, where and roughly how much, plus a photo if you have one. I will tell you what the assessment involves. WhatsApp +971 52 328 6185.

When to get urgent help

Spreading redness, increasing pain, heat, fever, discharge, or skin that turns white, grey or dark after an injection should not wait for an appointment. Seek urgent medical care.

Frequently asked questions

Not with hyaluronidase, which only breaks down hyaluronic acid. Collagenase has been described for selected Ellansé nodules in a small case series,6 but it is not a universal dissolver. Management depends on what the lump actually is.

No. It can be a non-inflammatory deposit of product, a firm or fibrotic area, a delayed inflammatory nodule, a true foreign-body granuloma, or occasionally infection. Ultrasound helps tell these apart.

Not necessarily. Some lumps relate to volume and placement, but delayed inflammatory nodules and granulomas can occur even when the injection was done well.

Some small, non-inflammatory lumps soften over time. Others persist while the product is present, which depends on the version used. A scan helps decide whether to wait, treat or investigate further.

Not automatically. Steroid can be appropriate in selected inflammatory lesions, but it can thin the skin and the fat beneath it, so I decide only after examining and scanning the area.

My personal practice is a maximum of 2 ml in one session. This is my own limit, not an official guideline.

Yes. You do not need to have been my patient before.

Diagnose first, then decide.

A lump after Ellansé is not automatically a granuloma, and it does not automatically need an injection. The first step is finding out what it actually is.
About the author. Dr Shiva Faramarzi, MD, is an aesthetic, regenerative and longevity physician at Apogee Clinic, JBR, Dubai (DHA licence 43705219). This article is patient education and does not replace the advice of your own doctor.

References

1.  de Melo F, Nicolau P, Piovano L, et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé). Clin Cosmet Investig Dermatol. 2017;10:431-440. doi:10.2147/CCID.S145195
2.  Chiang C, Peng J, Peng H. Filler-induced granuloma from polycaprolactone-based collagen stimulator injection in the tear trough area: a case report. J Cosmet Dermatol. 2021;20(5):1529-1531. doi:10.1111/jocd.14010
3.  Hong J, Sun B, Shin S, Kim B. Late-onset filler-induced granuloma after polycaprolactone-based filler treated with high-intensity focused ultrasound and quantum molecular resonance technology. Dermatol Surg. 2022;48(6):693-694. doi:10.1097/DSS.0000000000003424
4.  Wu et al. Point-of-care ultrasound (POCUS) for precision management in Ellanse-treated patients. J Cosmet Dermatol. 2025;24(6):e70262. doi:10.1111/jocd.70262
5.  Shekarriz P, Shojaee P. Ultrasound-assisted management of filler-related complications: report of a successful treatment of delayed-onset nodules related to polycaprolactone-based filler. Clin Case Rep. 2022;10(11):e6646. doi:10.1002/ccr3.6646
6.  Wu et al. iCare technique of dissolving Ellanse M nodules using collagenase: a case series and experimental study. J Cosmet Dermatol. 2025;24(5):e70201. doi:10.1111/jocd.70201
7.  Flores Rodríguez JC, Porras Zamora BM, Rico Macías NM, et al. The management of poly-L-lactic acid (PLLA) nodules: a scoping review and evidence-mapped clinical pathway. Cureus. 2026;18(6):e110742. doi:10.7759/cureus.110742
8.  Weinhammer A, Shields B, Keenan T. Intralesional corticosteroid-induced hypopigmentation and atrophy. Dermatol Online J. 2020;26(1). doi:10.5070/d3261047199

Latest Post

A case study in facial harmonisation: nose, cheeks, lips and chin planned as one treatment, for proportion rather than volume.
On 11 November 2026 at 11:11 pm, Olivia Phillips and I recorded the first episode of my podcast, Evidence Before Trends: who creates beauty trends?
Stem cells cannot replace your hormones, but they may help what estrogen loss does to skin, hair and tissue repair. What the evidence shows, and what it does not.

Newsletter

Evidence-based updates on longevity and aesthetic medicine, from Dr Shiva.

Subscribe on LinkedIn

Prefer email? Subscribe by email. You will be asked to confirm.